^
Association details:
Biomarker:FGFR3 L496V
Cancer:Urothelial Cancer
Drug:Truseltiq (infigratinib) (FGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations

Excerpt:
BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression….Given the rather heterogeneous array of alterations observed in this cohort, it is challenging to draw any firm conclusions regarding the nature of FGFR3 alterations and response to BGJ398....FGFR3 resistance mutations, including FGFR3 gatekeeper mutations (V443L, V443M, and L496V), as determined by preclinical studies, were detected in the cfDNA of four patients during treatment.
DOI:
10.1158/2159-8290.CD-18-0229